{"preliminary_commentary":{"by_channel":{"x_thread":45,"podcast":4,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05863195\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"EA2222","nct_id":"NCT05863195","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ea2222-nct05863195. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients undergo surgery to place the HAI pump within 6 weeks of randomization, followed by single SPECT/CT on study. Patients then receive floxuridine via the HAI pump within 12 weeks of randomization on study. Patients also receive one of the following standard chemotherapy regimens per the treating physician within 16 weeks of randomization: FOLFOX IV, FOLFIRI IV, or OX/IRI IV with or without cetuximab IV and/or panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or MRI scans throughout the trial.","label":"Arm A (HAI, floxuridine, standard chemotherapy)","type":"EXPERIMENTAL"},{"description":"Patients receive one of the following standard chemotherapy regimens per the treating physician within 6 weeks of randomization: FOLFOXIRI IV, FOLFOX IV, FOLFIRI IV, or OX/IRI IV with or without cetuximab IV, panitumumab IV, and/or bevacizumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may receive capecitabine PO in substitution for fluorouracil at the discretion of the investigator and may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or MRI scans throughout the trial.","label":"Arm B (standard chemotherapy)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-06-30","type":"ESTIMATED"},"conditions":["Metastatic Colorectal Carcinoma","Metastatic Malignant Neoplasm in the Liver","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Carcinoma"],"enrollment":{"count":408,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Bevacizumab","otherNames":["ABP 215","ABP-215","ABP215","Alymsys","Anti-VEGF","Anti-VEGF Humanized Monoclonal Antibody","Anti-VEGF Monoclonal Antibody SIBP04","Anti-VEGF rhuMAb","Avastin","Avegra","Avzivi","Aybintio","BAT 1706","BAT-1706","BAT1706","BAT1706 Biosimilar","Bevacizumab awwb","Bevacizumab Biosimilar ABP 215","Bevacizumab Biosimilar BAT1706","Bevacizumab Biosimilar BEVZ92","Bevacizumab Biosimilar BI 695502","Bevacizumab Biosimilar CBT 124","Bevacizumab Biosimilar CT-P16","Bevacizumab Biosimilar FKB238","Bevacizumab Biosimilar GB-222","Bevacizumab Biosimilar HD204","Bevacizumab Biosimilar HLX04","Bevacizumab Biosimilar IBI305","Bevacizumab Biosimilar LY01008","Bevacizumab Biosimilar MB02","Bevacizumab Biosimilar MIL60","Bevacizumab Biosimilar Mvasi","Bevacizumab Biosimilar MYL-1402O","Bevacizumab Biosimilar QL 1101","Bevacizumab Biosimilar QL1101","Bevacizumab Biosimilar RPH-001","Bevacizumab Biosimilar SCT501","Bevacizumab Biosimilar Zirabev","Bevacizumab-adcd","Bevacizumab-aveg","Bevacizumab-awwb","Bevacizumab-aybi","Bevacizumab-bvzr","Bevacizumab-byva","Bevacizumab-equi","Bevacizumab-maly","Bevacizumab-nwgd","Bevacizumab-onbe","Bevacizumab-tnjn","BP102","BP102 Biosimilar","Byvasda","CT P16","CT-P16","CTP16","Equidacent","FKB 238","FKB-238","FKB238","HD204","IBI 305","IBI-305","IBI305","Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer","Jobevne","MB 02","MB-02","MB02","Mvasi","MYL-1402O","Onbevzi","Oyavas","PF 06439535","PF-06439535","PF06439535","QL1101","Recombinant Humanized Anti-VEGF Monoclonal Antibody","rhuMab-VEGF","SCT501","SIBP 04","SIBP-04","SIBP04","Vegzelma","Zirabev"],"type":"BIOLOGICAL"},{"name":"Capecitabine","otherNames":["Ro 09-1978/000","Xeloda"],"type":"DRUG"},{"name":"Cetuximab","otherNames":["C 225","C-225","C225","Cetuxa","Cetuximab Biosimilar CDP-1","Cetuximab Biosimilar CMAB009","Cetuximab Biosimilar KL 140","Cetuximab-cetu","Chimeric Anti-EGFR Monoclonal Antibody","Chimeric MoAb C225","Chimeric Monoclonal Antibody C225","ENZ 124","ENZ-124","ENZ124","Erbitux","IMC-C225"],"type":"BIOLOGICAL"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Floxuridine","otherNames":["2'-Deoxy-5-fluorouridine","5-Fluoro-2'-deoxyuridine","5-Fluorodeoxyuridine","5-Fluorouracil deoxyriboside","5-FUdR","FDUR","Floxuridin","Fluorodeoxyuridine","Fluorouridine Deoxyribose","Fluoruridine Deoxyribose","FUdR","WR 138720","WR-138720","WR138720"],"type":"DRUG"},{"name":"Fluorouracil","otherNames":["5 Fluorouracil","5 Fluorouracilum","5 FU","5-Fluoro-2,4(1H, 3H)-pyrimidinedione","5-Fluorouracil","5-Fluracil","5-Fu","5FU","AccuSite","Carac","Fluoro Uracil","Fluouracil","Flurablastin","Fluracedyl","Fluracil","Fluril","Fluroblastin","Ribofluor","Ro 2-9757","Ro-2-9757"],"type":"DRUG"},{"name":"Implantation","otherNames":[],"type":"PROCEDURE"},{"name":"Intrahepatic Infusion Procedure","otherNames":["HAI","Hepatic Arterial Infusion","Hepatic Artery Infusion","IHI","Intrahepatic Infusion"],"type":"PROCEDURE"},{"name":"Irinotecan","otherNames":[],"type":"DRUG"},{"name":"Leucovorin","otherNames":["Folinic acid"],"type":"DRUG"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Oxaliplatin","otherNames":["1-OHP","Ai Heng","Aiheng","Dacotin","Dacplat","Diaminocyclohexane Oxalatoplatinum","Eloxatin","Eloxatine","Elplat","JM 83","JM-83","JM83","Oxalatoplatin","Oxalatoplatinum","RP 54780","RP-54780","RP54780","SR 96669","SR-96669","SR96669"],"type":"DRUG"},{"name":"Panitumumab","otherNames":["ABX-EGF","ABX-EGF Monoclonal Antibody","ABX-EGF, Clone E7.6.3","E7.6.3","Human IgG2K Monoclonal Antibody","MoAb ABX-EGF","MoAb E7.6.3","Monoclonal Antibody ABX-EGF","Monoclonal Antibody E7.6.3","Vectibix"],"type":"BIOLOGICAL"},{"name":"Single Photon Emission Computed Tomography","otherNames":["Medical Imaging, Single Photon Emission Computed Tomography","Single Photon Emission Tomography","Single-Photon Emission Computed","single-photon emission computed tomography","SPECT","SPECT imaging","SPECT SCAN","SPET","ST","tomography, emission computed, single photon","Tomography, Emission-Computed, Single-Photon"],"type":"PROCEDURE"}],"last_update":"2026-09-24","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"From randomization to death from any cause, assessed up to 5 years"}],"references":[],"start_date":{"date":"2024-04-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","url":"https://clinicaltrials.gov/study/NCT05863195"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ea2222-nct05863195"}